Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details Textual)

v3.3.1.900
Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Operating Loss Carryforwards [Line Items]        
Income tax benefit from release of deferred tax assets valuation allowance $ 93,400,000      
Increase in equity when deferred tax assets are realized 33,900,000      
Approximate amount of federal net operating loss carryforward that may not be utilized 50,900,000      
Reversal of uncertain tax benefits 0 $ 3,190,000 $ 0  
Income tax expense from Pfizer Transaction 2,300,000      
Income Taxes (Textual) [Abstract]        
Total gross unrecognized tax benefit 8,595,000 5,890,000 9,231,000 $ 9,245,000
Increase in unrecognized tax benefit 3,500,000      
Decrease in unrecognized tax benefit 800,000      
Unrecognized tax benefits that would impact effective tax rate 700,000 $ 900,000 $ 200,000  
Approximate unrecognized tax benefits $ 100,000      
Minimum        
Operating Loss Carryforwards [Line Items]        
Tax credit expiration period 15 years      
Estimated tax exposure $ 0      
Maximum        
Operating Loss Carryforwards [Line Items]        
Tax credit expiration period 20 years      
Estimated tax exposure $ 50,000,000      
Research and Development Tax Credit Carryforwards        
Operating Loss Carryforwards [Line Items]        
Research and development tax credit carryforwards 7,400,000      
Federal        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards 362,400,000      
State        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards 199,900,000      
Foreign        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards 126,600,000      
Foreign | OPKO Biologics        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards $ 112,900,000